Clinical trial registry record

First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 10, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07637981
Last registry update
June 10, 2026
Status
Recruiting
Phase
Phase 2
Sponsor
Dendrogenix
Enrollment
24
Countries
Belgium
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
24
Population
ALL · 18 Years to 75 Years
Duration
2026-05-13 to 2027-10-01
Intervention
DX243; Placebo
Comparator
Placebo
Outcomes measured
Safety and tolerability: incidence, nature, severity and causality of treatment emergent adverse events (TEAE) and (Ser…; Tolerability at the injection sites using a 1-5 scale Common Terminology Criteria for Adverse Events (CTCAE) for pain,…; Number of participants with at least one clinically significant abnormal laboratory result — For 7 months; Number of Participants With Abnormal ECG Findings — For 7 months; Change in Pure Tone Audiometry — For 7 months; Change in speech audiometry — For 7 months; Hearing Handicap Inventory for the Elderly- Screening (HHIE-S) questionnaire score — For 7 months; Severity of tinnitus — For 7 months; Distorsion Product OtoAcoustic Emission (DPOAE) — For 7 months; Quality of Life (QoL) assessed using 15iSSQ scale — For 7 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Hearing ageing · 60%Source terminology contains: age-related hearing loss. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

hearing aging
Open primary sourceExport JSON